Nova Mentis Life Science Corp. (NOVA.CN)
CAD 0.01
(N/A%)
CAD 0.01
(N/A%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -8088.00 CAD | 96.97% |
| 2022 | -266.51 Thousand CAD | -21.85% |
| 2021 | -218.73 Thousand CAD | 89.76% |
| 2020 | -2.13 Million CAD | -2354.22% |
| 2019 | -87 Thousand CAD | 78.38% |
| 2018 | -402.39 Thousand CAD | 66.77% |
| 2017 | -1.21 Million CAD | -85.08% |
| 2016 | -654.34 Thousand CAD | -288.45% |
| 2015 | -168.45 Thousand CAD | -87.16% |
| 2014 | -90 Thousand CAD | -5574.91% |
| 2013 | -1586.00 CAD | 45.18% |
| 2012 | -2893.00 CAD | 98.86% |
| 2011 | -253.79 Thousand CAD | 8.11% |
| 2010 | -276.19 Thousand CAD | -27.79% |
| 2009 | -216.13 Thousand CAD | 38.72% |
| 2008 | -352.69 Thousand CAD | -94.48% |
| 2007 | -181.34 Thousand CAD | 23.58% |
| 2006 | -237.29 Thousand CAD | -476.38% |
| 2005 | -41.17 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 38.17 Thousand CAD | 572.05% |
| 2024 Q2 | 47.94 Thousand CAD | 25.57% |
| 2023 Q3 | -24.44 Thousand CAD | -40.13% |
| 2023 Q1 | -113.94 Thousand CAD | 57.25% |
| 2023 Q2 | -17.44 Thousand CAD | 84.69% |
| 2023 FY | -8088.00 CAD | 96.97% |
| 2023 Q4 | -8088.00 CAD | 66.91% |
| 2022 FY | -266.51 Thousand CAD | -21.85% |
| 2022 Q2 | -634.35 Thousand CAD | 43.85% |
| 2022 Q4 | -266.51 Thousand CAD | 42.31% |
| 2022 Q1 | -1.12 Million CAD | -416.52% |
| 2022 Q3 | -461.95 Thousand CAD | 27.18% |
| 2021 FY | -218.73 Thousand CAD | 89.76% |
| 2021 Q4 | -218.73 Thousand CAD | 71.49% |
| 2021 Q3 | -767.18 Thousand CAD | 31.59% |
| 2021 Q2 | -1.12 Million CAD | 25.52% |
| 2021 Q1 | -1.5 Million CAD | 29.48% |
| 2020 Q1 | -73.46 Thousand CAD | 15.57% |
| 2020 FY | -2.13 Million CAD | -2354.22% |
| 2020 Q2 | -475.67 Thousand CAD | -547.51% |
| 2020 Q3 | -289.92 Thousand CAD | 39.05% |
| 2020 Q4 | -2.13 Million CAD | -636.49% |
| 2019 Q4 | -87 Thousand CAD | 12.3% |
| 2019 Q1 | -102.36 Thousand CAD | 74.56% |
| 2019 FY | -87 Thousand CAD | 78.38% |
| 2019 Q2 | -177.51 Thousand CAD | -73.41% |
| 2019 Q3 | -99.21 Thousand CAD | 44.11% |
| 2018 Q4 | -402.39 Thousand CAD | 35.77% |
| 2018 FY | -402.39 Thousand CAD | 66.77% |
| 2018 Q1 | -1.54 Million CAD | -27.74% |
| 2018 Q2 | -1.08 Million CAD | 29.57% |
| 2018 Q3 | -626.49 Thousand CAD | 42.5% |
| 2017 Q1 | -824.19 Thousand CAD | -25.96% |
| 2017 Q4 | -1.21 Million CAD | -89.72% |
| 2017 Q3 | -638.34 Thousand CAD | 12.44% |
| 2017 Q2 | -729.07 Thousand CAD | 11.54% |
| 2017 FY | -1.21 Million CAD | -85.08% |
| 2016 Q3 | -11.02 Thousand CAD | 78.69% |
| 2016 Q2 | -51.74 Thousand CAD | 47.57% |
| 2016 FY | -654.34 Thousand CAD | -288.45% |
| 2016 Q1 | -98.68 Thousand CAD | 41.42% |
| 2016 Q4 | -654.34 Thousand CAD | -5835.06% |
| 2015 Q1 | -17.72 Thousand CAD | 80.31% |
| 2015 Q3 | -25.77 Thousand CAD | -829.98% |
| 2015 Q4 | -168.45 Thousand CAD | -553.44% |
| 2015 FY | -168.45 Thousand CAD | -87.16% |
| 2015 Q2 | -2772.00 CAD | 84.36% |
| 2014 Q4 | -90 Thousand CAD | 12.85% |
| 2014 Q1 | -1553.00 CAD | 2.08% |
| 2014 FY | -90 Thousand CAD | -5574.91% |
| 2014 Q3 | -103.26 Thousand CAD | -1467.53% |
| 2014 Q2 | -6588.00 CAD | -324.21% |
| 2013 Q2 | -1944.00 CAD | 85.18% |
| 2013 FY | -1586.00 CAD | 45.18% |
| 2013 Q4 | -1586.00 CAD | -18.18% |
| 2013 Q3 | -1342.00 CAD | 30.97% |
| 2013 Q1 | -13.11 Thousand CAD | -353.47% |
| 2012 Q4 | -2893.00 CAD | 0.0% |
| 2012 Q3 | - CAD | 100.0% |
| 2012 Q1 | -7179.00 CAD | 97.17% |
| 2012 FY | -2893.00 CAD | 98.86% |
| 2012 Q2 | -1066.00 CAD | 85.15% |
| 2011 Q2 | -147.26 Thousand CAD | 42.89% |
| 2011 Q3 | -1.14 Million CAD | -678.78% |
| 2011 Q4 | -253.79 Thousand CAD | 77.87% |
| 2011 FY | -253.79 Thousand CAD | 8.11% |
| 2011 Q1 | -257.85 Thousand CAD | 6.64% |
| 2010 Q4 | -276.19 Thousand CAD | -196.21% |
| 2010 Q1 | -281.95 Thousand CAD | -30.45% |
| 2010 Q3 | -93.24 Thousand CAD | 42.29% |
| 2010 FY | -276.19 Thousand CAD | -27.79% |
| 2010 Q2 | -161.57 Thousand CAD | 42.7% |
| 2009 Q3 | -535.19 Thousand CAD | -745.68% |
| 2009 Q4 | -216.13 Thousand CAD | 59.62% |
| 2009 FY | -216.13 Thousand CAD | 38.72% |
| 2009 Q1 | -156.98 Thousand CAD | 55.49% |
| 2009 Q2 | -63.28 Thousand CAD | 59.69% |
| 2008 Q2 | -394.93 Thousand CAD | -230.76% |
| 2008 Q4 | -352.69 Thousand CAD | 37.68% |
| 2008 FY | -352.69 Thousand CAD | -94.48% |
| 2008 Q3 | -565.91 Thousand CAD | -43.29% |
| 2008 Q1 | -119.4 Thousand CAD | 34.16% |
| 2007 Q4 | -181.34 Thousand CAD | 25.69% |
| 2007 Q2 | -631.74 Thousand CAD | 44.19% |
| 2007 FY | -181.34 Thousand CAD | 23.58% |
| 2007 Q1 | -1.13 Million CAD | -377.05% |
| 2007 Q3 | -244.03 Thousand CAD | 61.37% |
| 2006 Q3 | -620.34 Thousand CAD | -4765.84% |
| 2006 Q2 | -12.74 Thousand CAD | 0.0% |
| 2006 Q4 | -237.29 Thousand CAD | 61.75% |
| 2006 FY | -237.29 Thousand CAD | -476.38% |
| 2005 FY | -41.17 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -125.08 Thousand CAD | 93.534% |
| Asep Medical Holdings Inc | -44.72 Thousand CAD | 81.915% |
| BetterLife Pharma Inc. | 207.85 Thousand CAD | 103.891% |
| BioVaxys Technology Corp. | -977.00 CAD | -727.84% |
| ChitogenX Inc. | 3.84 Million CAD | 100.211% |
| Rapid Dose Therapeutics Corp. | 2.29 Million CAD | 100.353% |
| Defence Therapeutics Inc. | 1.68 Million CAD | 100.479% |
| Entheon Biomedical Corp. | -344.63 Thousand CAD | 97.653% |
| Gemina Laboratories Ltd. | 284.33 Thousand CAD | 102.845% |
| Glow Lifetech Corp. | 116.15 Thousand CAD | 106.963% |
| Lexston Life Sciences Corp. | -390.4 Thousand CAD | 97.928% |
| Pharmala Biotech Holdings Inc. | 58.49 Thousand CAD | 113.827% |
| Doseology Sciences Inc. | -1.06 Million CAD | 99.237% |
| MYND Life Sciences Inc. | 2.99 Million CAD | 100.27% |
| PharmaTher Holdings Ltd. | -2.13 Million CAD | 99.621% |
| PreveCeutical Medical Inc. | 3.83 Million CAD | 100.211% |
| Telescope Innovations Corp. | -719.49 Thousand CAD | 98.876% |